Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $170.7 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 46.49% to $170.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $170.7 million through Dec 2025, down 46.49% year-over-year, with the annual reading at $170.7 million for FY2025, 46.49% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $170.7 million at Intellia Therapeutics, down from $319.1 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $319.1 million in Q4 2024, with the low at $170.7 million in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $236.8 million, with a median of $238.1 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities increased 27.21% in 2024, then crashed 46.49% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $254.2 million in 2021, then grew by 2.47% to $260.5 million in 2022, then dropped by 3.72% to $250.8 million in 2023, then increased by 27.21% to $319.1 million in 2024, then plummeted by 46.49% to $170.7 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $170.7 million, $319.1 million, and $250.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.